AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
4.360
+0.080 (1.87%)
At close: Apr 24, 2026, 4:00 PM EDT
4.340
-0.020 (-0.46%)
After-hours: Apr 24, 2026, 4:10 PM EDT
AN2 Therapeutics Market Cap
AN2 Therapeutics has a market cap or net worth of $156.22 million as of April 24, 2026. Its market cap has increased by 299.25% in one year.
Market Cap
156.22M
Enterprise Value
98.22M
1-Year Change
299.25%
Ranking
Category
Stock Price
$4.36
Market Cap Chart
Since the IPO on March 25, 2022, AN2 Therapeutics's market cap has decreased from $281.10M to $156.22M, a decrease of -44.42%. That is a compound annual growth rate of -13.39%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 24, 2026 | 156.22M | 400.09% |
| Dec 31, 2025 | 31.24M | -24.24% |
| Dec 31, 2024 | 41.23M | -93.23% |
| Dec 29, 2023 | 609.40M | 229.57% |
| Dec 30, 2022 | 184.91M | -34.22% |
| Mar 25, 2022 | 281.10M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| ProQR Therapeutics | 163.31M |
| Spero Therapeutics | 158.62M |
| Oramed Pharmaceuticals | 155.72M |
| Molecular Partners AG | 155.64M |
| Humacyte | 155.41M |
| Fate Therapeutics | 154.63M |
| Galectin Therapeutics | 153.38M |
| Alps Group | 149.76M |